

Ontario Public Drug Programs

Drug Submission Status

Report for December 2016

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Ciclopirox	Penlac	ciclopirox	8% w/w	topical solution	02298953
Mylan Pharmaceuticals ULC	Mylan-Rivastigmine Patch 5	Exelon Patch 5	rivastigmine	9mg/5 sq cm	transdermal patch	02423413
Mylan Pharmaceuticals ULC	Mylan-Rivastigmine Patch 10	Exelon Patch 10	rivastigmine	18mg/10 sq cm	transdermal patch	02423421
Sandoz Canada Inc.	Sandoz Rivastigmine Patch 5	Exelon Patch 5	rivastigmine	9mg/5 sq cm	transdermal patch	02426293

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Sandoz Canada Inc.	Sandoz Rivastigmine Patch 10	Exelon Patch 10	rivastigmine	18mg/10 sq cm	transdermal patch	02426307
Teva Canada Limited	Teva-Cinacalcet	Sensipar	cinacalcet HCl	30mg	FC tablet	02441624
Teva Canada Limited	Teva-Cinacalcet	Sensipar	cinacalcet HCl	60mg	FC tablet	02441632
Teva Canada Limited	Teva-Cinacalcet	Sensipar	cinacalcet HCl	90mg	FC tablet	02441640